Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6)....

Full description

Bibliographic Details
Main Authors: Kazufumi Takamatsu, Satoshi Marumo, Motonari Fukui, Atsuko Hata
Format: Article
Language:English
Published: Elsevier 2017-08-01
Series:Journal of Microbiology, Immunology and Infection
Subjects:
Aging
Antiviral drugs
Geriatrics
Gerontology
High-risk patient
Neuraminidase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S1684118217300750
Description
Summary:We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6). Results confirm intravenous peramivir's usefulness.
ISSN:1684-1182

Similar Items